Further TRK Inhibitor Development

Video

Shubham Pant, MD:Tell me, there are other TRK inhibitors out there. So we talked a little bit about entrectinib you said it got like a breakthrough designation. How does that target the TRK? How is it different from other TRK inhibitors?

David S. Hong, MD:So entrectinib is different than larotrectinib in the sense that it also targets ALK, ROS. And the most recent data that came out were also at ESMO [European Society for Medical Oncology 2018 Congress]. Dr George D. Demetri, MD, presented those data. He’s from Dana-Farber Cancer Institute. And in that dataset there was I think about 55 patients. The response rates were slightly lower than larotrectinib, about 57%. As I shared with you, the actual adverse event profile was a little bit more different. The most common adverse effect being dysgeusia.

Shubham Pant, MD:And that was with entrectinib.

David S. Hong, MD:Yes.

Shubham Pant, MD:So as you said entrectinib followed larotrectinib, you said it’s more for like dizziness or…

David S. Hong, MD:Yes. Fatigue.

Shubham Pant, MD:Fatigue was the big one, yes.

David S. Hong, MD:So what’s also interesting is that in the entrectinib dataset they did reach a median, it’s called duration of response, of around 10 months, which at this point with larotrectinib—the dataset that we have of the 55 patients, the initial dataset—we have not even reached a median duration of response. Over 80% of the patients with larotrectinib do appear to at 1 year still maintain their response.

Shubham Pant, MD:All these seem to be durable responses. That means it’s not like one of those drugs that the response happens and then it goes away.

David S. Hong, MD:Correct. And whether that’s entirely because of larotrectinib or just the biology…

Shubham Pant, MD:The biology of the disease, like in slower growing salivary gland tumors.

David S. Hong, MD:It’s not entirely clear yet. And the numbers are too small I think right now for both the entrectinib and larotrectinib for us to make any clear comparisons. I know there are a lot of people who would like to make comparisons between those.

Shubham Pant, MD:But these are different trials, so you cannot cross-compare trials.

David S. Hong, MD:At this point, yes.

Transcript edited for clarity.


Recent Videos
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Martin H. Voss, MD, an expert on kidney cancer
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Related Content